AOD-9604 in Chirac — Fat Loss Peptide Research Guide
AOD-9604 research guide for Chirac. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Chirac looking to source AOD-9604, the key fact to understand is that this compound is available only through an online research supply market. What this means for Chirac researchers is that your location matters far less than your ability to verify analytical documentation — and those verification methods are within reach of all serious researchers. Separating quality AOD-9604 from the rest of the market depends on three things: an HPLC chromatogram confirming ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to evaluate AOD-9604 vendors rigorously — the standards covered in this guide are universal across all research contexts.
The Science Behind AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Chirac comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying AOD-9604: Quality Markers to Look For
Before looking at individual vendors, build a clear picture of what a proper COA looks like — so you can recognise whether a vendor meets it. A COA for AOD-9604 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. For Chirac researchers evaluating vendors with limited track records: a test quantity before committing to research volumes before placing larger orders is what experienced peptide researchers consistently do. Keep lyophilised AOD-9604 at minus 20 degrees Celsius until ready to use; reconstitute only the amount needed for the near-term protocol and return unused portion to the freezer.
Order AOD-9604 — ships to Chirac
COA-verified · International tracking · Research grade
Research compound status for AOD-9604 means risk characterisation relies on animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Proper handling of AOD-9604 requires strict sterile technique during reconstitution — alcohol-swabbed septum, fresh needles, clean working environment — and temperature control throughout the entire workflow. Bacterial endotoxin contamination is the most serious safety risk specific to research peptides — verify endotoxin testing is documented in your batch COA before any injectable research application. PubMed and related preprint servers are the primary literature resources for AOD-9604 research; favour indexed journal publications over preprints over case reports or anecdotal evidence.
Frequently Asked Questions
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
